达雷妥尤单抗联合CyBorD治疗新诊断AL淀粉样变性:ANDROMEDA研究安全性导入期结果
ANDROMEDA是一项3期研究,评估达雷妥尤单抗联合环磷酰胺、硼替佐米和地塞米松(CyBorD)对比CyBorD治疗新诊断AL淀粉样变性。本文报告28例安全性导入期结果:皮下达雷妥尤单抗联合CyBorD耐受性良好,无新的安全性问题,血液学总缓解率96%,完全血液学缓解15例(54%),并观察到器官缓解。
要点
- 皮下达雷妥尤单抗联合CyBorD耐受性良好,无新的安全性问题。
- 血液学总缓解率96%,完全血液学缓解15例(54%)。
- 12个月时肾脏缓解10/15例,心脏缓解8/13例,肝脏缓解2/3例。
核心结论
- 达雷妥尤单抗联合CyBorD耐受性良好,与静脉制剂相比无新的安全性问题,并显示出稳健的血液学和器官缓解。
研究设计与样本
- 3期ANDROMEDA研究(NCT03201965)的安全性导入期,纳入28例新诊断AL淀粉样变性患者。
- 患者接受皮下达雷妥尤单抗联合CyBorD治疗,CyBorD每周给药共6个周期。
主要发现
- 患者中位受累器官数为2个(肾脏68%,心脏61%),中位治疗周期数为16(范围1-23)。
- 治疗中出现的不良事件与皮下达雷妥尤单抗在多发性骨髓瘤中的表现及CyBorD一致,1例发生1级输注相关反应。
- 无5级治疗中出现的不良事件;5例患者死亡,其中3例发生在移植后。
- 血液学总缓解率为96%,完全血液学缓解15例(54%);至少部分缓解在1、3、6个月分别为20例、22例、17例。
- 3、6、12个月时肾脏缓解分别为6/16例、7/15例、10/15例,心脏缓解分别为6/16例、6/13例、8/13例;12个月时肝脏缓解为2/3例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care. Based on outcomes of daratumumab in multiple myeloma (MM), the phase 3 ANDROMEDA study (NCT03201965) is evaluating daratumumab-CyBorD vs CyBorD in newly diagnosed AL amyloidosis. We report results of the 28-patient safety run-in. Patients received subcutaneous daratumumab (DARA SC) weekly in cycles 1 to 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter for up to 2 years. CyBorD was given weekly for 6 cycles. Patients had a median of 2 involved organs (kidney, 68%; cardiac, 61%). Patients received a median of 16 (range, 1-23) treatment cycles. Treatment-emergent adverse events were consistent with DARA SC in MM and CyBorD. Infusion-related reactions occurred in 1 patient (grade 1). No grade 5 treatment-emergent adverse events occurred; 5 patients died, including 3 after transplant. Overall hematologic response rate was 96%, with a complete hematologic response in 15 (54%) patients; at least partial response occurred in 20, 22, and 17 patients at 1, 3, and 6 months, respectively. Renal response occurred in 6 of 16, 7 of 15, and 10 of 15 patients, and cardiac response occurred in 6 of 16, 6 of 13, and 8 of 13 patients at 3, 6, and 12 months, respectively. Hepatic response occurred in 2 of 3 patients at 12 months. Daratumumab-CyBorD was well tolerated, with no new safety concerns versus the intravenous formulation, and demonstrated robust hematologic and organ responses. This trial was registered at www.clinicaltrials.gov as #NCT03201965.
引用
- Palladini G, Kastritis E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020. PMID: 32244252. doi:10.1182/blood.2019004460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。